<?xml version="1.0" encoding="utf-8" ?><rss version="2.0"><channel><title>Bing: Cour Complet En JavaScript 11</title><link>http://www.bing.com:80/search?q=Cour+Complet+En+JavaScript+11</link><description>Search results</description><image><url>http://www.bing.com:80/s/a/rsslogo.gif</url><title>Cour Complet En JavaScript 11</title><link>http://www.bing.com:80/search?q=Cour+Complet+En+JavaScript+11</link></image><copyright>Copyright © 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.</copyright><item><title>Coursera | Courses, Professional Certificates, and Degrees Online</title><link>https://www.coursera.org/</link><description>Learn in-demand skills with online courses and Professional Certificates from leading companies like Google, IBM, Meta, and Adobe. Explore flexible programs—from short courses to full degrees.</description><pubDate>Thu, 23 Apr 2026 00:27:00 GMT</pubDate></item><item><title>Reprogramming the immune system. Restoring lives. | COUR Pharma</title><link>https://courpharma.com/</link><description>Reprogramming the immune system. Restoring lives. At COUR, we develop targeted therapies that incite calm within the immune system and help restore the health of people suffering from autoimmune diseases.</description><pubDate>Mon, 20 Apr 2026 21:38:00 GMT</pubDate></item><item><title>Coursera, Inc. (COUR)</title><link>https://finance.yahoo.com/quote/COUR/</link><description>Find the latest Coursera, Inc. (COUR) stock quote, history, news and other vital information to help you with your stock trading and investing.</description><pubDate>Tue, 21 Apr 2026 23:53:00 GMT</pubDate></item><item><title>Cour inks $940M-plus autoimmune deal with Roche's Genentech</title><link>https://www.fiercebiotech.com/biotech/cour-links-roches-genentech-autoimmune-deal-could-exceed-940m</link><description>Roche’s Genentech unit has tapped Cour to help develop and commercialize the biotech’s bespoke tolerogenic nanoparticle treatments for autoimmune diseases, Cour said Tuesday.</description><pubDate>Tue, 03 Dec 2024 07:57:00 GMT</pubDate></item><item><title>After 10 Years of Hard Work, COUR Treads Into Pharma’s ... - BioSpace</title><link>https://www.biospace.com/business/after-10-years-of-hard-work-cour-treads-into-pharmas-myasthenia-gravis-territory</link><description>COUR will be facing some major Big Pharma peers in myasthenia; Argenx’s Vyvgart was approved for the disease in 2021 while Johnson &amp; Johnson has filed for approval of nipocalimab and Amgen recently trumpeted positive late-stage results.</description><pubDate>Tue, 18 Feb 2025 05:00:00 GMT</pubDate></item><item><title>Massachusetts Court System | Mass.gov</title><link>https://www.mass.gov/orgs/massachusetts-court-system</link><description>The Massachusetts court system consists of the Supreme Judicial Court, the Appeals Court, the Executive Office of the Trial Court, the 7 Trial Court departments, the Massachusetts Probation Service, and the Office of Jury Commissioner.</description><pubDate>Mon, 06 Apr 2026 09:59:00 GMT</pubDate></item><item><title>COUR: Coursera Inc Latest Stock Price, Analysis, News and ... - Stocktwits</title><link>https://stocktwits.com/symbol/COUR</link><description>Get real-time Coursera Inc (COUR) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.</description><pubDate>Sun, 19 Apr 2026 07:13:00 GMT</pubDate></item><item><title>Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease</title><link>https://www.biopharmadive.com/news/cour-nanoparticle-autoimmune-biotech-startup-series-a/705979/</link><description>Biotechnology startup Cour Pharmaceuticals has raised $105 million to advance a portfolio of medicines for autoimmune diseases. The startup’s funding was co-led by Alpha Wave Ventures and Lumira Ventures and involved large drugmakers Roche, Pfizer and Bristol Myers Squibb.</description><pubDate>Tue, 30 Jan 2024 20:07:00 GMT</pubDate></item><item><title>COUR Pharma - LinkedIn</title><link>https://www.linkedin.com/company/courpharma</link><description>With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.</description><pubDate>Mon, 14 Mar 2022 04:50:00 GMT</pubDate></item><item><title>COUR - Coursera Stock Price - Barchart.com</title><link>https://www.barchart.com/stocks/quotes/COUR</link><description>Coursera's Path to Profitability Gets Another Quarter to Prove Itself—or Not Immediate access to this special report (delivered via PDF) with actionable insights to the upcoming COUR earnings release.</description><pubDate>Mon, 13 Apr 2026 04:50:00 GMT</pubDate></item></channel></rss>